Effects of exercise therapy on prostate cancer indicators

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of exercise therapy on signs of prostate cancer in men with low-risk localized prostate cancer who are undergoing active surveillance. Participants will be assigned to either a structured home-based walking program or continue their usual exercise routines. The exercise therapy will be supervised by an exercise physiologist, and the outcomes will be compared to assess the effectiveness of the intervention. The study aims to provide insights into how exercise may influence cancer indicators without providing direct treatment for the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18
* Men with histologically confirmed localized prostate cancer undergoing active surveillance.
* Inactive, defined as not meeting the national exercise guidelines for cancer patients (\<150 minutes/week of moderate or vigorous exercise)43 as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry (general physical activity screening assessment via smart watch).
* Screening clearance by an MSK Exercise Physiologist (i.e., review of ECG)
* BMI \<40 kg/m\^2
* Cleared for exercise participation as per pre-screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) (Appendix B)

Exclusion Criteria:

* Enrollment in any other program that may alter the impact of exercise on tumor outcomes (e.g., weight loss program)
* Any neoadjuvant anticancer treatment of any kind for prostate cancer in the last 5 years
* Any history of systemic anticancer therapy in the last 15 years
* Distant metastatic malignancy of any kind
* Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting
• University of California, Los Angeles (Data and Specimen Analysis Only)
  Los Angeles, California, United States Not yet recruiting
• Hartford Healthcare Alliance (Data collection only)
  Hartford, Connecticut, United States Not yet recruiting
• Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
  Basking Ridge, New Jersey, United States Not yet recruiting
• Memorial Sloan Kettering Monmouth (Limited protocol activities)
  Middletown, New Jersey, United States Not yet recruiting
• Memorial Sloan Kettering Bergen (Limited protocol activities)
  Montvale, New Jersey, United States Not yet recruiting

Study contacts

• Principal investigator: Lee Jones — City of Hope Medical Center
• Study coordinator: Lee Jones
• Email: leejones@coh.org
• Phone: 6262184673

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Two-fraction radiotherapy for localized prostate cancer

  This study is testing if giving radiotherapy in just two sessions instead of five can effectively treat localized prostate cancer while causing fewer side effects for patients.

  Recruiting UMC Utrecht · Utrecht · NCT06518226

• MRI-based microboost SBRT with de-escalated whole-gland radiation for localized prostate cancer

  This study tests whether giving a focused 45 Gy microboost to MRI-defined lesions with smaller whole-gland doses (30 or 35 Gy) is safe and effective for men with low- to intermediate-risk localized prostate cancer.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia · NCT07644598

• Lower-dose radiation to parts of the prostate for some men with prostate cancer

  This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07635238

• Short-term hormone therapy with PSMA PET/CT before prostate removal for high-risk localized prostate cancer

  This trial will test whether giving short-term androgen-deprivation therapy (ADT) before prostate removal lowers PSMA PET signal and helps predict recurrence risk in men with localized high-risk prostate cancer.

  Recruiting Phase 2 Baptist Health South Florida · Miami, Florida · NCT07455903

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.